Alterations of cardiac ERK1/2 expression and activity due to volume overload were attenuated by the blockade of RAS

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 1, 2010, Pages 84-92

  Zhang, Weihua ^a   Elimban, Vijayan ^a   Xu, Yan Jun ^a   Zhang, Ming ^a   Nijjar, Mohinder S ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

ACE inhibitors; AT1 receptor antagonists; Cardiac hypertrophy; Heart failure; MAPK expression

Indexed keywords

ENALAPRIL; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR ELK 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTOCAVAL FISTULA; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEART RIGHT VENTRICLE; HEART VENTRICLE OVERLOAD; HEART VOLUME; HEART WEIGHT; LIVER WEIGHT; LUNG WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, ABDOMINAL; CARDIOMEGALY; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE; HEMODYNAMICS; LOSARTAN; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 76649085797     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409356430     Document Type: Article

References (41)

1. Schluter KD, Piper HM Regulation of growth in the adult cardiomyocytes. FASEB J. 1999 ; 13 (suppl): S17 - S22.
2. Bogoyevitch MA, Andersson MB, Gillespie-Brown J., et al. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J. 1996 ; 314 (pt 1). 115-121.
3. Shimizu N., Yoshiyama M., Omura T., et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res. 1998 ; 38 (1). 116-124.
4. Kim S., Iwao H. Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn J Pharmacol. 1999 ; 80 (2). 97-102.
5. Ma XL, Kumar S., Gao F., et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999 ; 99 (13). 1685-1691.
6. Wollert KC, Drexler H. The rennin-angiotensin system and experimental heart failure. Cardiovas Res. 1999 ; 43 (4). 838-849.
7. Yoshida K., Yoshiyama M., Omura T., et al. Activation of mitogen-activated protein kinases in the non-ischemic myocardium of an acute myocardial infarction in rats. Jpn Circ J. 2001 ; 65 (9). 808-814.
8. Bogoyevitch MA, Sugden PH The role of protein kinases in adaptational growth of the heart. Int J Biochem Cell Biol. 1996 ; 28 (1). 1-12.
9. Ruzicka M., Yuan B., Harmsen E., Leenen FH The reninangiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993 ; 87 (3). 921-930.
10. Ruzicka M., Leenen FH Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation. 1995 ; 91 (1). 16-19.
11. Garcia R., Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990 ; 24 (5). 430-432.
12. Wang X., Ren B., Liu S., Sentex E., Tappia PS, Dhalla NS Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol. 2003 ; 94 (2). 752-763.
13. Xu YJ, Chapman D., Dixon IM, et al. Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation. J Cell Mol Med. 2004 ; 8 (1). 85-92.
14. Xu YJ, Saini HK, Zhang M., Elimban V., Dhalla NS MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res. 2006 ; 72 (1). 163-174.
15. Bradford MM A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254.
16. Gille H., Kortenjann M., Thomae O., et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 1995 ; 14 (5). 951-962.
17. Huang M., LeBlanc MH, Hester RL Evaluation of the needle technique for producing an arteriovenous fistula. J Appl Physiol. 1994 ; 77 (6). 2907-2911.
18. Huang M., Hester RL, Guyton AC Hemodynamic changes in rats after opening an arteriovenous fistula. Am J Physiol Heart Circ Physiol. 1992 ; 262 (3 pt 2). H846 - H851.
19. Sadoshima JI, Malhotra R., Izumo S. The role of the cardiac rennin-angiotensin system in load-induced cardiac hypertrophy. J Cardiac Failure. 1996 ; 2 (4 suppl). S1 - S6.
20. Yano M., Kim S., Izumi Y., Yamanaka S., Iwao H. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res. 1998 ; 83 (7). 752-760.
21. Marais R., Wynne J., Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 1993 ; 73 (2). 381-393.
22. Lou H., Danielson I., Singal PK Involvement of mitogen activated protein kinases in adriaycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005 ; 2884 (): H1925 - H1930.
23. Bueno OF, Molkentin JD Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002 ; 91 (9). 776-781.
24. Dent MR, Das S., Dhalla NS Alterations in both death and survival signals for apoptosis in heart failure due to volume overload. J Mol Cell Cardiol. 2007 ; 43 (6). 726-732.
25. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990 ; 81 (4). 1161-1172.
26. Rumberger JA Ventricular dilatation and remodeling after myocardial infarction. Mayo Clin Proc. 1994 ; 69 (7). 664-674.
27. Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 1991 ; 4 (4 pt 2). 334S - 340S.
28. Schunkert H., Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990 ; 86 (6). 1913-1920.
29. Dhalla NS, Shao Q., Panagia V. Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev. 1998 ; 2 (4). 261-272.
30. McAlpine HM, Morton JJ, Leckie B., Rumley A., Gillen G., Dargie HJ Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988 ; 60 (2). 117-124.
31. AokiH., RichmondM., IzumoS., SadoshimaJ. Specificroleoftheextracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000 ; 347 (pt 1). 275-284.
32. Yamazaki T., Komuro I., Shiojima I., Yazaki Y. Angiotensin II mediates mechanical stress-induced cardiac hypertrophy. Diabetes Res Clin Pract. 1996 ; 30 (suppl): 107-111. (Pubitemid 126352584)
33. Zou Y., Komuro I., Yamazaki T., et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996 ; 271 (52). 33592-33597.
34. Naveri L. The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand Suppl. 1995 ; 630: 1-48.
35. Urata H., Healy B., Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 ; 66 (4). 883-890.
36. Senbonmatsu T., Saito T., Landon EJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 2003 ; 22 (24). 6471-6482.
37. Gohike P., Linz W., Scholkens BA, et al. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension. 1994 ; 23 (4). 411-418.
38. Guo X., Wang J., Elimban V., Dhalla NS Both enalapril and losartan attenuate sarcolemmal Na+-K+ ATPase remodeling in failing rat heart due to myocardial infarction. Can J Physiol Pharmacol. 2008 ; 86 (4). 139-147.
39. Wang J., Guo X., Dhalla NS Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril and losartan. Biophys Biochem Acta. 2004 ; 1690 (2). 177-184.
40. Shao Q., Ren B., Elimban V., Tappia PS, Takeda N., Dhalla NS Modification of sarcolemmal Na+-K+ ATPase and Na+-Ca2+ exchanger expression in heart failure by blockade of reninangiotensin system. Am J Physiol Heart Circ Physiol. 2005 ; 288 (6). H2637 - H2646.
41. Hirata Y., Hayakawa H., Kakoki M., et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension. 1996 ; 27 (3 pt 2). 672-678.